Key facts
- It has raised $1.5M.
- Notable investors include 50 Partners, CHMBR Partners, EIT Health, Les Business Angels des Grandes Écoles, Roma Tecnopolo Spazio Attivo BIC Lazio.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Medicud
- ·The full record, as it builds
Funding rounds
No funding rounds for Medicud are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Medicud
Developer of a negative pressure wound therapy system designed for incisional wounds. The company's system combines effectiveness with patient comfort by offering constant negative pressure throughout treatment, all in a portable and cost-effective design along with the use of bio-sourced polymers and the absence of electronics, reducing the system's ecological impact, enabling patients with a cost-effective, user-friendly, and discrete system for wound healing.
- Sector
- Healthcare
- HQ
- Rome, Italy
- Founded
- 2020
- Employees
- 10
- Website
- medicud.it/
- Ownership
- Privately Held (backing)
Medicud doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Medicud shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Medicud in its N-PORT filings yet. We sweep new filings monthly.